LLY•benzinga•
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact
Summary
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga